DEVELOPMENT OF AN IMMUNOTHERAPY PLATFORM FOR THE TREATMENT OF SARCOMA PATIENTS THANKS TO THE JOINT ACTIVITY OF RSI OF ODR (OPBG AND IFO) AND COMPANIES (TAKIS AND PLAISANT) THE PROJECT AIMS TO DEVELOP A THERAPEUTIC PROTOTYPE FINOALL' CLINICAL APPLICABILITY FOR PATIENTS WITH SARCOMAshare on FacebookTwitterLinkedinEmailreport an issue